Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: June 10, 2025 (Events reported range from April 2024 to July 2025)
Business Overview: The filing details material definitive agreements regarding debt restructuring, warrant issuance, and equity sales under an existing Equity Line of Credit (ELOC).
Key Financial Metrics and Transactions
- Debt Restructuring: Amended a $100,000 promissory note with The Tiger Cub Trust (controlled by CEO Jacob D. Cohen). The note bears 18% annual interest, compounded monthly.
- Equity Issuance (ELOC): Sold 261,667 shares of common stock to Platinum Point Capital under the ELOC agreement.
- Proceeds: $409,367 (net of fees, discounts, and expenses).
- Price per Share: $1.564458.
- Debt Conversion: Indigo Capital LP converted a $500,000 principal note plus $90,000 accrued interest into 393,333 shares of common stock at $1.50 per share.
- Warrant Issuance: Granted Tiger Cub Trust warrants to purchase 50,000 shares at an exercise price of $1.815 per share, expiring July 21, 2028.
Material Changes and Agreements
Amended and Restated Convertible Promissory Note (A&R Note):
- Conversion Price: Set at $1.785 per share (the greater of $1.50 or specific market-based formulas).
- Maximum Dilution: Full conversion of the $100,000 principal plus $18,000 accrued interest could result in the issuance of 66,107 shares.
- Terms Change: The "Mandatory Prepayment" requirement upon a Qualified Financing was removed.
Equity Line of Credit (ELOC) Activity:
- The Company utilized the ELOC with Platinum Point Capital, which allows for up to $25,000,000 in total commitments over a 2-year term.
- The June 10, 2025 transaction represents a specific drawdown under this facility.
Guidance, Risks, and Contingencies
- Related Party Transactions: The debt restructuring involves The Tiger Cub Trust, controlled by the CEO and Chairman, Jacob D. Cohen. This introduces potential conflicts of interest and related party risk.
- Dilution Risk: The filing highlights potential dilution from the conversion of the Tiger Cub Note (up to 66,107 shares), the exercise of Tiger Cub Warrants (50,000 shares), and the recent ELOC sale (261,667 shares).
- Regulatory Exemptions: All securities issued (A&R Note, Warrants, ELOC shares, and Indigo conversion) were sold pursuant to exemptions from registration (Section 4(a)(2), Rule 506, or Section 3(a)(9)) and are subject to transfer restrictions.
- Liquidity Strategy: The company is actively utilizing convertible debt and equity lines to raise capital, indicating a reliance on these instruments for liquidity rather than traditional bank financing.
Investor Verification Checklist
- Verify the current cash balance and burn rate to assess the necessity of the $100,000 related-party loan and ELOC drawdown.
- Confirm the total outstanding principal and accrued interest on all convertible notes to calculate potential future dilution.
- Review the full text of the Amended and Restated Convertible Promissory Note (Exhibit 10.3) for specific default triggers and acceleration clauses.
- Monitor the remaining capacity under the $25,000,000 ELOC with Platinum Point Capital and the frequency of future drawdowns.
- Check for any subsequent filings regarding the exercise of the Tiger Cub Warrants or further conversions of the Indigo Capital note.